Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
June 1, 2015
Imaging study highlighted at ASCO reveals many women may receive wrong HER2 therapy
Solna, June 1, 2015. – Affibody AB today announced the presentation of a clinical study at American Society of Clinical Oncology (ASCO).
Read more
Affibody AB and Biotest AG enter into a Research License and Option Agreement regarding the Albumod™ platform
Dreieich, Germany and Solna, Sweden – Biotest AG and Affibody AB today announced that the companies have signed a Research License and Option Agreement.
May 25, 2015
Kallelse till årsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma tisdagen den 23 juni 2015 kl 13.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
May 19, 2015
Interim Report – January to March 2015
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
February 27, 2015
Year End Report 2014
November 27, 2014
Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma
Oslo, Norway and Solna, Sweden – Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop...
November 20, 2014
Interim Report – January to September 2014
August 22, 2014
Interim Report – January to June 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its...
May 20, 2014
Interim Report – January to March 2014
